![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/5/57/Copanlisib.svg/640px-Copanlisib.svg.png&w=640&q=50)
Copanlisib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Copanlisib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Copanlisib, sold under the brand name Aliqopa,[1] is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.[1][2]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Aliqopa |
Other names | BAY 80-6946 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617044 |
License data |
|
Routes of administration | Intravenous |
Drug class | PI3-Kinase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 84.2%[1] |
Metabolism | CYP3A4/5 (≈90%), CYP1A1 (≈10%)[1] |
Elimination half-life | 39.1 hours (range: 14.6 to 82.4)[1] |
Excretion | Feces (64%), Urine (22%); 14% were not recovered[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H28N8O4 |
Molar mass | 480.529 g·mol−1 |
3D model (JSmol) | |
| |
|
Close